Jane Mayrin, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1467679738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $541,899 of the $627,863 with a category attached, or 86.3%. 57 manufacturers reported payments, led by Lilly USA, LLC at 43.5% of the total. Reporting peaked in 2019 at $213,074 and has fallen 78.8% since, to $45,209 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,754 payments — averaging $357.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$273K
- Novo Nordisk$163K
- AstraZeneca$65K
- Sanofi-aventis U.S. LLC$60K
- Amarin Pharma, Inc.$36K
- Johnson & Johnson$13K
- plus $19K from 51 others
What the payments were for
- Consulting fees$7,8801%
- Speaking & faculty fees$541,89986%
- Travel & lodging$40,7026%
- Food & beverage$37,1516%
- Education$1710%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$97,866
- Ozempic$81,572
- MOUNJARO$75,922
- FARXIGA$63,252
- BAQSIMI$59,350
- RYBELSUS$51,802
- SOLIQUA 100/33$40,310
- Vascepa$34,867
- TOUJEO$20,076
- Tresiba$14,937
- INVOKANA$12,675
- Minimed 630G$3,881
- Victoza$3,655
- Pogo Automatic Blood Glucose Monitoring System$2,242
- UNITHROID$500
- ZENPEP$250
- Korlym$232
- MINIMED 780G$125
- Creon$125
- JARDIANCE$125
How this compares
$627,863 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 1,481 | $1,452,489 |
| OzempicSemaglutide | 1,071 | $1,073,281 |
| ProliaDenosumab | 437 | $745,890 |
| FarxigaDapagliflozin Propanediol | 898 | $573,492 |
| JardianceEmpagliflozin | 670 | $493,189 |
| TradjentaLinagliptin | 533 | $315,512 |
| KerendiaFinerenone | 378 | $313,394 |
| VascepaIcosapent Ethyl | 765 | $291,777 |
| MounjaroTirzepatide | 262 | $280,235 |
| JanuviaSitagliptin Phosphate | 268 | $182,452 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 62 | $152,300 |
| ZenpepLipase/Protease/Amylase | 127 | $151,824 |
| Tresiba Flextouch U-200Insulin Degludec | 199 | $134,270 |
| CreonLipase/Protease/Amylase | 99 | $130,868 |
| TymlosAbaloparatide | 47 | $123,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $272,962 | $1,732,7241,743 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Wegovy | $162,583 | $1,184,5941,170 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,080 | $898,191499 claims |
| Boehringer IngelheimJardiance, Tradjenta | $953 | $808,7011,203 claims |
| AstraZenecaFarxiga | $65,166 | $573,492898 claims |
| BayerKerendia | $819 | $313,394378 claims |
| AbbVieCreon, Synthroid | $673 | $164,503750 claims |
| Aimmune Therapeutics, Inc.Zenpep | $366 | $151,824127 claims |
| Radius Health, Inc.Tymlos | $796 | $123,54547 claims |
| Johnson & JohnsonInvokana | $12,891 | $62,599102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
- Vijay BahlPittsburgh$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.